Bullish & Foolish
Full OKUR fundamentals All 466 on the Survival Watch

OKURONKURE THERAPEUTICS, INC.

Is Onkure Therapeutics struggling financially?

Yes, by its own account. Onkure Therapeutics told the SEC on 5 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$159.6M
Source filing
10-Q 5 May 2026
Balance sheet
30 Jun 2026

Cash runway

32+ mo

Runs out some time after Mar 2029, raising nothing.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$166.5M

÷

Cash burned over the last 12 months

$51.9M

What Onkure Therapeutics told the SEC

…adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. As of December 31, 2025, the Company had determined that substantial doubt about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However,…

ONKURE THERAPEUTICS, INC., Form 10-Q, filed 5 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 136.7% share-count increase The company issued stock. Each share now owns 57.7% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 42% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt